ABSTRACT-To examine the effects of a specific cysteinyl leukotriene (cysLT) antagonist, pranlukast, on allergic rhinitis, antigen-induced rhinitis in guinea pigs was modified by pretreatment with an cyclo oxygenase inhibitor (indomethacin) followed by an H1-blocker (pyrilamine). Intranasal ovalbumin (OVA) administration in actively sensitized guinea pigs resulted in concentration-dependent increases in nasal permeability and nasal airway resistance (NAR). Although pyrilamine (1 mg/kg, i.v.) abolished these antigen-induced changes, pretreatment with indomethacin (5 mg/kg, i.v.) followed by pyrilamine enhanced these responses to a degree similar to that observed with OVA challenge alone. Analyses of nasal perfusate in indomethacin/pyrilamine-pretreated animals showed that cysLTs increased by 270.8%, whereas throm boxane B2 decreased by 88.3% as compared with those on challenged with OVA alone. Oral administration of pranlukast (1-10 mg/kg) dose-dependently prevented increases in nasal permeability and NAR of indo methacin/pyrilamine-pretreated animals. However, an anti-allergic agent, azelastine, did not affect these responses. These results indicate that pranlukast suppresses antigen-induced cysLT-mediated responses of allergic rhinitis in actively sensitized guinea pigs. A cysLT antagonist, pranlukast, may thus prevent cysLT-mediated symptoms of allergic rhinitis.
Nasal symptoms of allergic rhinitis often display a biphasic pattern after antigen provocation.
While the early-phase symptoms (up to 1 hr after antigen provoca tion) such as sneezing and rhinorrhea are transient, the late-phase symptom (4 8 hr after antigen provocation) characterized by nasal congestion is persistent (1) . Media tors that have been suggested to participate in these symp toms include histamine, cyclooxygenase metabolites of arachidonic acid and cysteinyl leukotrienes (cysLTs) such as leukotriene C4, D4 and E4 (LTC4, LTD4 and LTE4), main components of the slow-reacting substance of anaphylaxis (SRS-A) (2) . Among these mediators, cysLTs are of particular interest as they have been suggested to play a role in nasal congestion (3, 4) , a symptom which is resistant to many therapeutic agents including current anti-histaminergics (5) . Thus, agents that may antagonize or inhibit the action of cysLTs (anti-cysLTs) may be use ful in the treatment of allergic rhinitis.
Although interest has focused on the therapeutic effects of anti-cysLTs against allergic rhinitis, current findings remain inconsistent. Clinical studies to evaluate the effects of anti-cysLTs on allergic rhinitis have produced controversial results (6, 7) , and there is lack of an ap propriate animal model for allergic rhinitis to evaluate relevant effects of anti-cysLTs. This study was designed to examine the effects of a specific cysLT antagonist, pranlukast, which has previously been demonstrated to be a useful agent for treatment of bronchial asthma (8) with a novel model of antigen-induced rhinitis in guinea pigs. We thus employed pretreatment with indomethacin followed by pyrilamine to pharmacologically modify and develop an antigen-induced cysLT-mediated response in guinea pigs (9) .
MATERIALS AND METHODS

Animals
Male Hartley guinea pigs (Nihon Rabbit, Osaka), weighing 300 to 600 g, were used throughout the experi ments. Animals were housed in an air-conditioned room at 23 -±:2C and 55 ± 5 010 humidity with a 12-hr light/dark cycle. Animals were given food and water ad libitum.
Chemicals
The synthesis of pranlukast (4-oxo-8-[4-(4-phenyl butoxy)benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran hemihydrate) and extraction of azelastine hydrochloride from Azeptine® (Eizai, Tokyo) were conducted in our laboratories. Other chemicals used in this study were: indomethacin, pyrilamine and ovalbumin (OVA) (Sigma, St. Louis, MO, USA); a specific radioimmunoassay kit for LTC4, LTD4 and LTE4 (Amersham International plc., Buckinghamshire, UK); Evans blue (Tokyo Kasei, Tokyo) and killed Bordetella pertussis (Kaketu Lab., Kumamoto). OVA, pyrilamine and Evans blue were dis solved in saline. Indomethacin was dissolved in 7010 so dium bicarbonate solution. Pranlukast and azelastine were suspended in 0.5010 sodium carboxymethylcellulose solution for oral administration.
Active sensitization
Guinea pigs were actively sensitized by i.p. injection of 1 mg of OVA containing 5 x 109 killed Bordetella pertus sis in 0.5 ml saline on day zero. The sensitized animals on day 14-21 post-OVA injection were used for experiments.
Antigen-induced rhinitis
Changes in nasal permeability: Sensitized guinea pigs, anesthetized with Nembutal (30 mg/kg, i.p.), were placed supine on a warm bed such that their rectal temperatures were maintained between 37C 38C. After tracheal transection, a cannula was inserted in the lung-side sec tion to maintain spontaneous respiration and was ligated to the trachea together with the gullet. Another cannula was inserted in the nasal-side section and the non-inserted open-end was connected to a perfusion pump for intra nasal perfusion at a rate of 0.19 ml/min. The right jugular vein was cannulated for drug administration. After 10-min washing with saline, 2%-Evans blue (2.5 ml/kg) was injected i.v. and perfused with saline for 10 min to obtain the basal value. Then, various concentra tions of OVA were perfused for 10 min per concentra tion. Thereafter, 10-min perfusion with saline was repeated five times. The collected perfusates were cen trifuged (1700 x g, 10 min), and cysLTs and thromboxane B2 (TXB2) concentrations in the supernatants were deter mined by radioimmunoassay (RIA) as described below. Dye contents measured spectrophotometrically at 620 nm were considered as an index of changes in nasal permeability. Indomethacin (5 mg/kg, i.v.) and pyril amine (1 mg/kg, i.v.), administered 3 and 1 min before OVA perfusion, eliminated possible effects attributed to endogenous prostaglandins and histamine, respectively.
Changes of nasal airway resistance: Sensitized guinea pigs, anesthetized with Nembutal (75 mg/kg, i.p.), were placed on a warm bed and cannulation of lungs and nasal cavities and other surgical procedures were repeated as described above. The lung cannula was connected to a constant volume respirator (Model SN-480-7; Shinano Apparatus, Tokyo), and the animals were artificially ven tilated with a constant volume of 5 ml at 70 strokes/min. The intranasal flow of nasal cavity cannula was aerated with an air pump at a rate of 500 ml/min. Changes in nasal airway resistance (NAR) under conditions of con stant airflow were measured with a pressure transducer (Validyne: Model DP 45-24-2114; Gould, Northridge, CA, USA) connected to the side-arm of the nasal cavity can nula. After stabilization of the air flow (5 min), the basal nasal airway pressure was measured. The air pump was then paused and OVA (0.03 -1010, 1 ml) was instilled into the nasal cavity for 5 min. After completely flushing out OVA with air, NAR was measured for 30 min. Indo methacin (5 mg/kg, i.v.) and pyrilamine (1 mg/kg, i.v.) were pretreated as described above. Measurement of cysLTs and TXB2: Contents of cysLTs were determined with a LTC4/D4/E4 multispecific RIA kit (Amersham International plc). The procedure for extrac tion was as follows: Briefly, 0.5 ml of nasal perfusate was mixed with 2 ml of ethanol, and then the mixture was al lowed to stand for 30 min at 4 °C followed by mixing. Af ter centrifugation at 1700 x g for 5 min at 4C, the super natant was evaporated to dryness. The dehydrated super natant was then dissolved in the assay buffer (0.05 M phosphate buffer, pH 7.4, containing 0.14 M NaCI and 0.01010 gelatin) and thereafter used as samples. Radioim munoassay was performed according to the kit manual. Briefly, aliquots of samples or standards were incubated with tracer ([3H]LTC4) and anti-cysLTs serum at 4 C for 18 24 hr. Dextran-coated charcoal was added to remove unbound cysLTs. After centrifugation of the suspension at 1700 x g for 10 min, the supernatants were transfered to a scintillation vial with 10 ml of scintillation fluid. Radioactivity was measured with a scintillation counter for 1 min. The cross-reactivities of this anti-serum to LTC4, LTD4 and LTE4 were 100010, 100% and 41%, respectively. This RIA is sensitive to 15.6 pg/50 ul of cysLTs.
Concentrations of TXB2 in the nasal lavage fluid were measured by the enzyme immunoassay manufacturer's protocol (Cayman Chemical Co., Ann Arbor, MI, USA) according to the kit manual. Briefly, aliquots of sample or standards were incubated with tracer TXB2 linked to acetylcholinesterase and anti-TXB2 serum on 96-well plates precoated with mouse monoclonal antibody for 18 hr at room temperature. The wells were washed with the supplied buffer and the substrate of acetylcholine, Ellman's reagent, was added to each well. After a 60 to 90-min incubation, the intensity of developed color was measured spectrophotometrically at 412 nm (range: 405-420 nm). The lower detection limit of this assay is 7.8 pg/ml.
Drug administration
Pranlukast and azelastine were orally administered 1 hr before OVA challenge in overnight-fasted animals.
Statistical analyses
Results are expressed as the mean±S.E.M. Student's t-test or two-way analysis of variance followed by Dun nett's t-test were used to verify statistical significance of difference between pairs of groups. P values of less than 0.05 were considered to be significant. Fig. 1 . Changes in nasal permeability in ac tively sensitized guinea pigs after nasal OVA perfusion. Control (10, n=6), pyrilamine pretreated (/, n=6) and pyrilamine/indo methacin-pretreated (A, n=6) animals were perfused with 1010 OVA solution for 10 min, and Evans blue contents in the perfusate were then measured at 10-min intervals for the indi cated periods. Saline-challenged animals (0, n =5) were perfused with saline instead of OVA solution. Pyrilamine and indomethacin were administered i.v. 1 and 3 min before OVA per fusion, respectively. Results are shown as the means ±S.E.M. of five to six animals. Statistical comparisons based on total dye content 0-60 min after OVA challenge between challenged and either saline or control animals where P<0.01 with Student's t-test are marked by ** and 0#
, respectively.
RESULTS
Nasal permeability in OVA-induced rhinitis Nasal perfusion with OVA concentration-dependently increased the permeability in actively sensitized animals at a concentration of less than 2%. The total amounts of dye recovered at 10-min intervals with 40-min perfusion with saline, 0.5%, 0.75%, 1% and 2% OVA were 4.3, 32.3, 56.1, 98.2 and 96.6 pg/40 min, respectively (N=3-5).
The significant increase in nasal permeability with 1010 OVA perfusion was comparable to that seen in a preliminary study on the concentration-response with OVA. The increase in permeability peaked 10 to 20 min after OVA perfusion and decreased thereafter. Pretreat ment of sensitized animals with the H1-blocker, pyril amine (1 mg/kg, i.v.), markedly reduced the increase in permeability due to OVA perfusion. However, in contrast, pretreatment with a cyclooxygenase inhibitor, indomethacin (5 mg/kg, i.v.) followed by pyrilamine
(1 mg/kg, i.v.), enhanced the permeability to a degree similar to that with OVA perfusion alone (Fig. 1) .
NAR in OVA-induced rhinitis We used 0.1010-OVA for instillation in this experiment as this concentration maximized the increase in NAR: For the area under the curve (AUC) analysis with saline, the NAR values induced by saline, 0.03%, 0.101o, 0.3010 and 1010-OVA were 139.3, 242.4, 313.7, 332.7 and 332.3 cmH2O • min, respectively (N= 5). As shown in Fig. 2 , OVA (0.1010) administration into the nasal cavity in creased NAR in actively sensitized guinea pigs with the effect peaking at 10 min post-antigen administration and persisting at high levels thereafter. Similar to nasal permeability, pretreatment of sensitized animals with pyrilamine (1 mg/kg, i.v.) markedly reduced the NAR response. However, in contrast, pretreatment with indo methacin (5 mg/kg, i.v.) followed by pyrilamine (1 mg/kg, i.v.) enhanced the NAR to a value similar to that induced by OVA alone.
Contents of cysL Ts and TXB2 in the nasal perfusate of OVA-induced rhinitis Nasal OVA (1%) perfusion increased the concentra tions of TXB2 (Fig. 3) , a stable metabolite of throm boxane A2 (TXA2), and cysLTs (Fig. 4) in the perfusate of sensitized guinea pigs. Both mediators peaked 10 to 20 min after OVA perfusion. Indomethacin (5 mg/kg) /pyrilamine (1 mg/kg)-pretreatment abolished the TXA2 increase (Fig. 3) but enhanced the cysLTs contents (Fig. 4)   Fig. 2 . Changes in nasal airway resistance (NAR) in actively sensitized guinea pigs after nasal OVA challenge. Control (0), pyrilamine-pretreated (/) and indometh acin/pyrilamine-pretreated (A) animals were nasally instilled with 0.1076 OVA solution. Nasal airway resistance was measured at 5 min intervals for the indicated periods. Saline-challenged animals (0) were instilled with saline instead of OVA solution. Animals were pretreated with pyrilamine and indo methacin as described in Fig. 1 . Results are shown as the means±S.E.M. of five animals. Statistical comparisons based on AUC be tween challenged and either saline or control animals where P<0.01 with Student's t-test are marked by ** and , respectively. perfusion. Guinea pigs were pretreated with pyrilamine and indomethacin as described in Fig. 1 . In the saline-challenged group, sensitized animals were challenged with saline. Either pranlukast or azelastine was administered 1 hr before OVA challenge.
Results are shown as the means ±S.E.M. of total dye content 0-60 min after OVA challenge in three to five animals. Statistical comparisons of the challenged group with either saline-treated animals where P < 0.05 () or control animals where P < 0.01 (**) were verified with Student's t-test or Dunnett's t-test, respectively. 
DISCUSSION
This study shows that indomethacin/pyrilamine pretreatment followed by nasal OVA challenge facilitated nasal permeability and NAR in actively sensitized guinea pigs. These increases, comparable to those induced by OVA alone, were associated with significantly enhanced cysLTs and decreased TXB2 in the nasal perfusate. The specific cysLT antagonist, pranlukast (10) dose-depend ently attenuated the nasal symptoms induced in indo methacin/pyrilamine-pretreated animals, whereas the anti allergic agent azelastine (11) did not affect these symp toms. This is the first report on a cysLT-dependent model of allergic rhinitis and its prevention by a cysLT antago nist.
Evaluation of agents that prevent the action of cysLTs (anti-cysLTs) in antigen-induced allergy models has been unreliable, because single antigen challenge generally induces only the histamine-dominated early-phase responses but not the late-phase response, where the involvement of cysLTs has been considered to be more prominent. In fact, the histamine-dependency of the early-phase response is supported by our results: pyril amine pretreatment potently blocked the OVA-induced increases in nasal permeability and NAR in sensitized guinea pigs (Figs. 1 and 2 ), whereas pranlukast did not prevent these responses at least at 10 mg/kg (p.o.) (un published data). In contrast, the cysLT-dependency of late phase response is best illustrated by the observation that cysLT antagonists more efficiently block the late phase bronchoconstriction than that in the early-phase in experimental models of bronchial asthma (12) .
Our findings, however, suggest that a single OVA challenge in sensitized guinea pigs can induce significant nasal symptoms even after eliminating the contributions of histamine and cyclooxygenase products of prostaglan dins by pyrilamine and indomethacin, respectively. These symptoms are cysLTs-dependent, as indicated by en hanced cysLTs in nasal perfusate and marked suppression of these symptoms by pranlukast. The cysLT-dependency is similar to that reported by Anderson et al. (13) who showed that pharmacological modification causes an tigen-induced cysLT-mediated bronchoconstriction in sensitized guinea pigs. It has been considered that pretreatment with indomethacin diverts metabolites of arachidonic acid to cysLTs by an alternate pathway, pos sibly by the lipoxygenase pathway (14) . Thus, our models may be useful for the study of agents with in vivo an tagonistic or inhibitory activities against cysLTs in an tigen-induced rhinitis. However, one must be careful to note that agents demonstrating efficacy in this model are not necessary considered to be effective on antigen-in duced rhinitis.
It has been reported that antigen-induced cysLT mediated increases in bronchial airway resistance display slower onset (1 to 2 min after antigen challenge) and de velopment when compared with those induced by anti gens alone in guinea pigs (9) , depicting the characteristic responses of cysLTs as SRS-A (9, 13). However, we did not observe such delays in pyrilamine/indomethacin pretreated animals, at least within the observation period of this study. This discrepancy may be due the different mechanisms of cysLTs action in increasing airway resistance at different sites. This suggests that LTD4 increases bronchial airway resistance via bronchocon striction (15) and increases NAR via edema probably due to increases in vascular permeability (16) and volume of nasal mucosa (17) . Follow-up studies within different time intervals are warranted to further characterize the cysLT-mediated response of antigen-induced rhinitis in guinea pigs.
An earlier study has shown that, on a weight basis, LTD4 is approximately 5000 times more potent than histamine in inducing nasal secretion and NAR increases in humans. Although the maximum response induced by LTD4 is less potent than that of histamine, the increase in NAR (an index of nasal congestion) is notably more per sistent and similar to that induced by antigens (3). Cys teinyl leukotrienes have been found during the late-phase in human nasal lavage fluid (18) . Although histamine is widely recognized as the major mediator of early-phase responses such as sneezing and rhinorrhea and anti histaminergics are effective against early-phase responses, these agents have negligible effects on nasal congestion (19, 20) . These results together with our observations that pranlukast potently reduced the increases in NAR and permeability support a potential role of cysLTs in allergic rhinitis, especially in relation to nasal congestion.
As shown in this study, pranlukast suppressed OVA induced increases in nasal permeability and NAR with ED50 values of 4.4 and 1.4 mg/kg in pyrilamine/indo methacin-pretreated animals, respectively. These values of pranlukast are similar to those reported previously in preventing antigen-induced cysLT-mediated increases in bronchial airway resistance (8) . These findings suggest that the antagonistic activities of this compound coincide with those effective against antigen-induced cysLT mediated bronchoconstriction and rhinitis symptoms. Thus, pranlukast may potently antagonize endogenous cysLTs in both the lower and upper airway.
Previous clinical studies with anti-cysLTs have been inconclusive. Although A-64077, a selective 5-lipoxygenase inhibitor, attenuates nasal congestion (21) , this com pound also inhibits the synthesis of LTB4 (22) . The effects of ICI 204,219 and L-649923 (potent cysLT antago nists) are controversial (6, 7) . Furthermore, since the antagonistic activities of these compounds on antigen induced rhinitis are unclear, the contributions of other pharmacological effects cannot be excluded in their dos ings. Therefore, cautious interpretation of results is war ranted, especially in understanding the effects of cysLTs on allergic rhinitis. On the other hand, azelastine has been reported to have both anti-cysLT and anti-histaminergic activity (23) , however this agent did not prevent cysLT mediated symptoms of allergic rhinitis at least in our syudy. In contrast to these agents, pranlukast may specifically antagonize the action of cysLTs in allergic rhinitis at a dose that has previously been used in clinical trials on bronchial asthma. Thus, it may be useful in un derstanding the effects of specific cysLT antagonism in allergic rhinitis. Results of a clinical trials with pranlukast against allergic rhinitis, which are currently under way, may provide answers to these questions.
